-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Globally, hepatocellular carcinoma (HCC) is a highly lethal malignant tumor and the second leading cause of cancer-related deaths
prevention
Recently, a number of studies have found that starting antiviral therapy in the early stage of CHB (that is, hepatitis B envelope antigen [HBeAg] is positive) may further reduce the risk of HCC
Researchers evaluated the incidence of HCC in Korean patients with chronic hepatitis B who started treatment with entecavir or tenofovir in the HBeAg positive or negative stage, and verified it in a white PAGE-B cohort
A total of 9143 South Korean CHB patients (average 49.
916 (10.
Correlation between HBeAg status and cumulative incidence of HCC in the entire cohort, liver cirrhosis cohort, and non-cirrhosis cohort of Korean patients (correspond to the figure in turn)
Correlation between HBeAg status and cumulative incidence of HCC in the entire cohort, liver cirrhosis cohort, and non-cirrhosis cohort of Korean patients (correspond to the figure in turn)Whether in the entire cohort or in the sub-cohort of patients with liver cirrhosis, no correlation was found between basal HBeAg positivity and HCC risk
Whether in Asia or in the entire cohort cohort of patients with cirrhosis and found no basis exists between HBeAg positive correlation with the risk of HCC in non-cirrhotic patients in sub-cohort, multivariate analysis showed a lower risk of HBeAg-positive and independently associated with HCC in In a sub-cohort of non-cirrhotic patients, multivariate analysis showed that HBeAg positive was independently associated with a lower risk of HCC
Correlation between HBeAg status and cumulative incidence of HCC in the entire white cohort, cirrhosis cohort, and non-cirrhosis cohort (correspond to the figure in turn)
Correlation between HBeAg status and cumulative incidence of HCC in the entire white cohort, cirrhosis cohort, and non-cirrhosis cohort (correspond to the figure in turn)In the white cohort (n=719, average 51.
In the white cohort , there was no correlation between HBeAg positivity and HCC risk
This multinational cohort study showed that HBeAg-positive status at the start of antiviral therapy may be an independent factor associated with a lower risk of HCC in patients with non-cirrhotic CHB, but not in patients with cirrhosis
HBeAg-positive status at the start of antiviral therapy may be an independent factor related to the lower risk of HCC in patients with non-cirrhotic CHB, but otherwise in patients with liver cirrhosis , the HBeAg-positive status at the start of antiviral therapy may be related to non-cirrhotic CHB patients Independent factors associated with a lower risk of HCC, but not in patients with cirrhosis
Original source:
Original source:Jang Heejoon, Yoon Jun Sik, Park Soo Young et al.
Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients with Chronic Hepatitis B
in this message
